hers Weight Loss Review 2026: Wegovy, Ozempic & Zepbound

The telehealth platform hers earns an Expert Score of 4.3 out of 5.0 from BestGuide, positioning it as a strong contender in the digital women’s health and weight management space. This comprehensive hers review evaluates its weight loss program, pricing structure, regulatory context, and the significant changes that followed Hims & Hers’ March 9, 2026 settlement with Novo Nordisk. Our analysis, drawing from 18 professional sources, finds hers is most effective for women who prioritize convenient, remote access to licensed medical providers and FDA-approved branded GLP-1 medications.

Many hers reviews praise the platform’s ease of use and rapid access to telehealth consultations. The 3.8/5 customer review score across 7,324 BBB reviews is meaningfully higher than the industry average for direct-to-consumer telehealth platforms and reflects positive user sentiment about ease of use, provider responsiveness, and medication delivery. However, BBB also notes that customer complaints concentrate on subscription cancellation and refund requests, with the parent company maintaining a no-returns refund policy for medications and personal care products. Prospective users should review the Terms and Conditions and Refund Policy carefully before subscribing.

Compare hers with other top-rated weight loss programs to see how it stacks up.

How the hers Weight Loss Program Works

The hers weight loss program operates as a 100% online telehealth service, connecting patients with licensed medical professionals to create a personalized treatment plan. The process is designed for convenience and can be completed from home in three primary steps, typically taking 24 to 72 hours from initial sign-up to receiving a treatment plan. hers uses asynchronous consultations (message-based provider review) as its primary model and does not require lab work prior to prescribing GLP-1 medications.

Step 1: Complete the Online Health Assessment

The journey begins with a detailed online intake form on the hers weight loss page. This confidential assessment takes approximately 5 to 10 minutes to complete and gathers information about medical history, weight loss goals, lifestyle, and any previous treatment attempts. This data provides a baseline for the medical provider to evaluate eligibility for prescription treatment.

Step 2: Consult with a Licensed Medical Provider

After submitting the assessment, hers connects you with a state-licensed medical provider for an asynchronous (message-based) consultation. The provider reviews your assessment, may ask follow-up questions, and determines if a prescription GLP-1 medication is clinically appropriate. To qualify for GLP-1 medications, patients typically need a Body Mass Index (BMI) of 30 or greater, or a BMI of 27 or greater with a weight-related health condition (such as Type 2 diabetes, hypertension, or high cholesterol). hers providers will not prescribe GLP-1s outside these clinical criteria.

Step 3: Receive Your Personalized Treatment Plan and Medication

If approved, the provider will prescribe a specific medication. Following the March 2026 Novo Nordisk partnership, hers primarily prescribes FDA-approved branded medications: Wegovy injectable (all doses including the new Wegovy HD 7.2mg), oral Wegovy, and Ozempic (off-label for weight loss). Eli Lilly’s Zepbound (tirzepatide) is also available through the platform. Your personalized plan, including medication shipped from a partner pharmacy, ongoing provider check-ins, and digital support content, is managed through the hers app or web platform.

Who Is hers Best For?

Based on BestGuide’s analysis, the hers weight loss program is best suited for women with a Body Mass Index (BMI) of 30 or greater (or BMI of 27 or greater with a qualifying weight-related health condition) who are seeking a medically supervised weight loss plan using FDA-approved GLP-1 medications. The platform is ideal for individuals who value the convenience of a 100% online telehealth model, eliminating the need for in-person doctor visits. It is a strong option for those with commercial insurance coverage that may reduce medication costs to $0 to $25 per month via the Novo Nordisk Savings Card, or for self-pay patients prepared for monthly medication costs of $249 to $399 plus the $149 membership fee. hers is not appropriate for individuals seeking weight loss medication outside the clinical BMI criteria, or for those who prefer in-person medical care.

Important Regulatory Context: March 2026 Novo Nordisk Settlement

Customers researching hers in 2026 should understand the significant changes to the platform’s weight loss program following federal regulatory action and a March 9, 2026 settlement with Novo Nordisk:

• February 2026: Hims & Hers launched a compounded oral semaglutide pill at $49 for the first month and $99 thereafter, drawing immediate regulatory scrutiny. The Department of Health and Human Services (HHS) referred Hims & Hers to the Department of Justice (DOJ) for potential violations of the Food, Drug & Cosmetics Act.
• March 9, 2026: Hims & Hers reached a settlement with Novo Nordisk (the patent holder for Wegovy and Ozempic). Under the agreement, Hims & Hers discontinued compounded semaglutide for new patients and became an authorized distribution channel for Novo Nordisk’s branded FDA-approved products.
• March 26, 2026: Hims & Hers launched access to branded Wegovy (all doses, including oral and injectable formulations) and Ozempic on its platform.
• Existing compounded patients: May continue on current protocols in limited circumstances, with full discontinuation expected by mid-2026.
• Eli Lilly’s Zepbound (tirzepatide): Also available on the platform through a separate arrangement.

This shift means hers no longer offers the low-cost compounded GLP-1s that were a primary differentiator earlier in 2026. The current platform model focuses on FDA-approved branded medications, with pricing competitive among telehealth platforms but materially higher than the discontinued compounded products. For consumers, this means medication safety and quality are now backed by FDA approval and Novo Nordisk’s manufacturing standards, with the trade-off of higher out-of-pocket cost for uninsured patients.

hers Standout Features

The hers platform distinguishes itself from traditional weight loss programs through several key features focused on modern medical treatments and digital convenience.

Access to FDA-Approved Branded GLP-1 Medications: Following the March 2026 Novo Nordisk partnership, hers provides telehealth access to FDA-approved Wegovy (injectable and oral) and Ozempic, plus Eli Lilly’s Zepbound. This positions hers as one of the largest authorized distribution channels for branded GLP-1 weight loss medications in the U.S. telehealth market.

Insurance Billing and Novo Nordisk Savings Card Integration: Unlike earlier in 2026 when compounded GLP-1s were self-pay only, branded medications through hers are now billable through commercial insurance. Combined with the Novo Nordisk Savings Card, eligible patients with commercial insurance may pay $0 to $25 per month for Wegovy.

Integrated Medical and Lifestyle Support: The monthly membership fee includes ongoing medical support, including asynchronous messaging with a care team and scheduled check-ins with the prescribing provider. The platform also provides access to curated content on nutrition and exercise, aiming for a more holistic approach than a simple prescription fulfillment service.

Comprehensive Women’s Health Platform: hers is not solely a weight loss company. It is part of a broader digital health platform that offers treatments for hair loss, mental health, sexual health, skincare, and primary care. This allows users to manage multiple health needs within a single ecosystem.

hers Pros and Cons

Is hers Legit?

Yes, hers is a legitimate telehealth company. hers is the female-focused brand of Hims & Hers Health, Inc., a publicly traded company on the New York Stock Exchange (NYSE: HIMS) since 2021. The company was founded in 2017 (incorporated July 6, 2017; business started December 30, 2013 per BBB records) and is led by co-founder and CEO Andrew Dudum. The corporate headquarters is at 2269 Chestnut St #523, San Francisco, CA 94123-2600.

As a medical service provider, hers is compliant with HIPAA regulations to protect patient privacy. All medical consultations are conducted by U.S.-licensed and board-certified healthcare professionals. The company partners with licensed pharmacies in the United States to dispense all medications. Following the March 9, 2026 settlement with Novo Nordisk, hers operates as an authorized distribution partner for FDA-approved branded GLP-1 medications, providing additional regulatory and quality assurance versus the previous compounded model.

Consumers should be aware that the telehealth model itself is subject to evolving regulatory scrutiny. In early 2026, Hims & Hers faced significant federal attention over its compounded GLP-1 launch, including an HHS referral to the DOJ for potential Food, Drug & Cosmetics Act violations. The March 2026 settlement with Novo Nordisk addressed these concerns by pivoting Hims & Hers to authorized FDA-approved product distribution. The company has since stabilized its weight loss program around branded medications.

hers BBB Rating and Accreditation

hers operates under the BBB profile of its parent company, Hims & Hers Inc., registered with BBB serving the San Francisco Bay Area and Northern Coastal California. Key details from the BBB profile:

• BBB Rating: A+ (highest possible letter grade).
• BBB Accreditation: Accredited since February 22, 2018.
• BBB File Opened: January 29, 2018.
• Years in Business: 12 (Business Started December 30, 2013; Business Incorporated July 6, 2017).
• Total Complaints: 3,977 in the last 3 years; 1,083 closed in the last 12 months.
• Customer Reviews: 3.8 out of 5 stars across 7,324 reviews.
• Business Management: Andrew Dudum, CEO.
• BBB Customer Complaint Notice: Per BBB, complaints concentrate on issues with cancelling orders and refund requests. BBB recommends users review the Terms and Conditions (with special attention to Subscription Products and Services) and the Refund Policy before subscribing.
• Refund and Exchange Policy: Per the BBB profile, Hims & Hers states: “Because of the nature of the products hims sells, all sales and payments made on, through or regarding the Site, the App and/or your User Account are final, irrevocable and not subject to or eligible for a refund. If you receive a package that is damaged or contains the wrong order, hims will try to replace it in a timely manner. Hims does not accept returns.”

The 3.8/5 customer review score across 7,324 reviews is a notable positive signal for a direct-to-consumer telehealth platform at this scale. For context, many large telehealth and consumer health companies see customer review scores below 1.5/5 on BBB. The A+ rating with BBB Accreditation since 2018 indicates BBB’s positive assessment of the company’s responsiveness to filed complaints and adherence to BBB Standards for Trust. However, the volume of complaints (3,977 over 3 years) and the no-returns refund policy are material considerations for prospective subscribers.

hers Cost: What You Should Expect to Pay

The cost structure for the hers weight loss program has two main components: the platform membership fee and the separate cost of medication. This is a critical distinction for calculating the total monthly expense. Pricing reflects the post-March 2026 transition to FDA-approved branded medications.

The minimum total monthly cost for a self-pay user on Oral Wegovy is approximately $398 ($149 membership + $249 medication). For uninsured patients on injectable Wegovy or Zepbound, the total monthly cost reaches $448 to $548. Eligible patients with commercial insurance and the Novo Nordisk Savings Card may see total costs as low as $149 to $174 per month. Customers should verify their insurance coverage and Savings Card eligibility before subscribing. Note that the membership fee does not include or guarantee a prescription, and is billed separately from medication.

Final Verdict: hers Review

After a thorough evaluation, hers earns an Expert Score of 4.3/5.0. It stands out as a convenient and accessible option for women seeking medically supervised weight loss with FDA-approved GLP-1 medications, through a modern telehealth platform. The platform’s greatest strengths are its streamlined process (provider review typically within 24 to 72 hours), authorized access to FDA-approved branded Wegovy, Ozempic, and Zepbound following the March 2026 Novo Nordisk partnership, and insurance integration that can substantially reduce medication costs for eligible patients. The BBB A+ Accredited status (since 2018) and 3.8/5 customer review score across 7,324 reviews provide solid trust signals at scale.

The score reflects several considerations that prevent a higher rating. First, the post-compounding pricing structure ($249 to $399 per month for branded medications, plus $149 membership) makes the platform meaningfully more expensive for uninsured patients compared to its pre-March 2026 offering. Second, the BBB profile shows 3,977 complaints over 3 years concentrated on subscription cancellation and refund issues, combined with a strict no-returns refund policy that limits consumer recourse. Third, hers uses asynchronous (message-based) consultations rather than video visits and does not require baseline lab work prior to prescribing GLP-1s, which some clinicians consider important for safe medical management.

For women with commercial insurance who can leverage the Novo Nordisk Savings Card, or for those who can afford the self-pay rates and value the convenience of telehealth, hers is a legitimate and effective option for FDA-approved GLP-1 weight loss treatment. For women without insurance coverage or on a tight budget, the all-in monthly cost may be prohibitive, and alternative telehealth platforms or insurance navigation through primary care may be worth comparing. As with any weight loss medication, patients should consult with a healthcare provider and consider the full risk-benefit profile, including potential side effects (gastrointestinal symptoms are common), the need for ongoing treatment to maintain results, and the possibility of weight regain after stopping medication.

See our full Buyers Guide for the best weight loss programs before making your decision.

Frequently Asked Questions About hers

What do experts say about hers weight loss?
BestGuide gives hers an Expert Score of 4.3 out of 5.0. Experts praise the platform for its post-March 2026 access to FDA-approved branded Wegovy, Ozempic, and Zepbound through its Novo Nordisk distribution partnership, and for its 3.8/5 customer review score across 7,324 BBB reviews (strong for the company’s scale). The main critiques are higher self-pay medication costs since the discontinuation of compounded semaglutide, async-only consultations, and a no-returns refund policy.

Is the hers weight loss program worth it in 2026?
For women with commercial insurance who can leverage the Novo Nordisk Savings Card (potentially reducing medication costs to $0 to $25 per month), hers is worth considering. For self-pay patients, total monthly costs of $398 to $548 (including the $149 membership) may be prohibitive. Customers should verify insurance coverage before subscribing.

How does hers compare to other weight loss programs?
hers is a medical telehealth platform, differing significantly from behavioral programs like Noom or diet-based plans like Weight Watchers. While others focus on psychological change and food tracking, hers focuses on medical intervention with FDA-approved GLP-1 medications, prescribed by licensed providers. Within the telehealth GLP-1 category, hers competes with Ro, Henry Meds, and Found Health.

Does hers weight loss work?
The hers weight loss program offers FDA-approved GLP-1 medications. According to STEP-1 clinical trial data for semaglutide 2.4mg (the active ingredient in Wegovy), participants achieved an average body weight loss of approximately 14.9% over 68 weeks when combined with diet and exercise. Newer Wegovy HD 7.2mg studies have shown mean weight loss of approximately 20.7%, with dysesthesia (abnormal skin sensation) occurring in 18.9% of patients. Individual results vary based on medication, dosage, adherence, lifestyle changes, and individual response. Discontinuing medication may result in weight regain.

How much does the hers GLP-1 program cost?
The total cost has two parts: a $149/month membership fee plus separate medication cost. As of 2026, branded medication options are Oral Wegovy ($249/mo), Injectable Wegovy ($299/mo), and Zepbound ($399/mo) for self-pay. Patients with commercial insurance and the Novo Nordisk Savings Card may pay $0 to $25/month for eligible Wegovy prescriptions.

Can I get Ozempic or tirzepatide through hers?
Yes. Following the March 2026 Novo Nordisk partnership, hers providers can prescribe FDA-approved branded Wegovy (semaglutide) and Ozempic (semaglutide, off-label for weight loss). Eli Lilly’s Zepbound (tirzepatide) is also available. hers no longer offers compounded semaglutide for new patients following the March 9, 2026 settlement with Novo Nordisk.

What happened to the hers compounded semaglutide?
In February 2026, Hims & Hers launched a compounded oral semaglutide pill at $49 for the first month. The launch drew federal regulatory scrutiny, with the Department of Health and Human Services referring Hims & Hers to the Department of Justice for potential Food, Drug & Cosmetics Act violations. On March 9, 2026, Hims & Hers reached a settlement with Novo Nordisk, agreeing to discontinue compounded semaglutide for new patients. Existing compounded patients may continue in limited circumstances, with full discontinuation expected by mid-2026. hers now operates as an authorized distribution partner for branded FDA-approved Wegovy and Ozempic.

What is the hers refund policy?
Per the parent company’s BBB-listed policy, “all sales and payments made on, through or regarding the Site, the App and/or your User Account are final, irrevocable and not subject to or eligible for a refund.” Hims & Hers does not accept returns. Damaged or incorrect orders may be replaced. Prospective customers should review the full Terms and Conditions and Refund Policy on the hers website before subscribing.

Does hers require lab work or video consultations?
No. hers uses asynchronous (message-based) consultations and does not require or order baseline lab work before prescribing GLP-1s. Some clinicians consider baseline labs (kidney function, A1C, thyroid) important for safe prescribing, so patients should discuss with their primary care provider whether independent lab work is appropriate.

Who is eligible for the hers GLP-1 weight loss program?
To qualify for GLP-1 medications through hers, patients typically need a Body Mass Index (BMI) of 30 or greater, or a BMI of 27 or greater with a weight-related health condition (such as Type 2 diabetes, hypertension, or high cholesterol). Patients outside these clinical criteria will not be approved.

Who owns hers?
hers is the female-focused brand of Hims & Hers Health, Inc., a publicly traded company on the New York Stock Exchange (NYSE: HIMS) since 2021. The company is led by co-founder and CEO Andrew Dudum and is headquartered at 2269 Chestnut St #523, San Francisco, CA 94123-2600.

What are the most common hers reviews complaints?
Based on the BBB profile (3,977 complaints over 3 years) and customer review data, the most common complaints involve issues with subscription cancellation and refund requests. The 3.8/5 customer review score across 7,324 reviews suggests overall user satisfaction is strong, but customers reporting issues most often cite the difficulty of cancelling subscriptions and the no-returns refund policy.